



News Release

Suven granted Certificate of Suitability (CEP) for Tamsulosin Hydrochloride

HYDERABAD, INDIA (August 18, 2008) – Suven Life Sciences Limited today announced that it has been granted the **first Certificate of Suitability (CEP)** by the **European Directorate for the Quality of Medicines (EDQM)** for its **API product Tamsulosin Hydrochloride**.

The European Directorate is one of the major institutions involved in the regulation and quality control of medicinal products authorized for use in Europe and overseas the European Pharmacopoeia (EP)

This **CEP** will simplify and make easier the registration procedures of our customers.

The role of **Certificate of Suitability** is to certify the compliance of a material with the requirements laid down in the relevant monograph of the European Pharmacopoeia (EP)

API's for which **CEP** has been granted are suitable for use in medicinal products. The **CEP's** are recognized by the 36 member states of the European union and additional countries like Australia, Canada and Switzerland etc.

Suven Life Sciences is a Hyderabad based Biopharmaceutical Company; a Collaborative Research Partner (CRP) since 2006 in Drug Discovery for global pharma major is a pioneer in Contract Research and Manufacturing Services (CRAMS) since 1995 and Drug Discovery Development Support Services (DDDSS) since 2005. Suven has been involved in development of path breaking technologies for global pharma companies for more than a decade. For more information, please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;